Lack of HBV reactivation among patients receiving immunomodulatory drugs in Egyptian cohort who underwent either close monitoring or Preemptive treatment.
Main Article Content
Keywords
HBV, HBVr, Vaccine, Autoimmune, Immunosuppressives, Preemptive treatment.
Abstract
Background: HBV reactivation is a preventable disease with high incidence among immunosuppressed. This can be attributed to either HBV virus widespread in the community or an inadequate assessment of HBV status prior to the start of the drug therapy.
Materials and strategies: A prospective cohort study included 200 patients with various autoimmune diseases prior to initiation of their immunosuppressives, with a 1 year follow up. Baseline liver biochemicals and HBV virology status were recorded for all patients, and they were arranged into 4 groups (Group A, previously vaccinated; Group B, HBV naïve; Group C, HBV disease and Group D, isolated HBV core). Group A was offered only follow-up, Group B were offered HBV immunization with follow up, and Groups C and D were offered either preemptive therapy or follow-up according to their risk of reactivation.
Results: The mean age was 26.5 years (22-34), 58.5% (117 patients) were female, 41.5% (83 patients) were male, our study group included 85 patients with IBD (54 patients with ulcerative colitis and 31 patients with Crohn’s disease), 54 patients with SLE, 41 patients with Bechet’s disease, 4 patients with rheumatoid arthritis and 16 patients with a variety of other autoimmune diseases. 93.5 % of patients have low risk for reactivation (as HBV status and the commenced drug), 3.5 % were moderate and only 3 % were at high risk. Group A included 43.5% (87 patients). Group B included 47.5 % (95 patients), group C was 4.50% (9 patients) and group D was 4.50% (9 patients). After 1 year follow up, Elevated liver enzymes were found in 10.3%, 20%, 66.7%, 44.4% of patients in group A, B, C and D respectively, pulse steroid therapy and positive HBsAg were the highest predictable values for elevated liver enzymes; However, no patients showed HBVr.
Conclusion: Monitoring with a proper assessment is needed for all patients prior to starting immunosuppressives or immunomodulatory drug therapy, there was a low prevalence of HBV among our cohort owing to the effective immunization programs. A close screen with no treatment is seen in HBV core positive patients who are prescribed moderate risk immunosuppressives; HBV core routine screening may be suggested for high-risk immunosuppressives only. HBV vaccine is essential prior to the immunosuppressives and HBsAb titre may not be impacted by the immune system or immunosuppressive medication. Preemptive therapy for HBsAg-positive patients on high-risk immunosuppressives is needed. However, longer follow-up studies with a larger sample size may be required.
References
2. Huang Q, Zhou B, Cai D, et al. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients. Hepatology 2021; 73:41.
3. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.
4. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020; 38:3698.
5. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148:221.
6. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61:703.
7. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.
8. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363.
9. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult-onsetstill's disease. J Rheumatol 2003; 30:1624.
10. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62:686.
11. Bessone F and Dirchwolf M. (2016) Management of hepatitis B reactivation in Consensus on theprevention, diagnosis, and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis; 8: 443 – 468
12. Sui M, Wu R, Hu X, et al. Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient
population, J Viral Hepat.Nov 2014;22(11):964
13. Su J and Lim JK. Hepatitis B Virus Reactivation in the Setting of Immunosuppressive Drug Therapy. Gastroenterology & Hepatology. 2019;15(11):585
14. Canzoni M, Marignani M, Sorgi ML, et al. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory
Rheumatic Diseases in Italy. Microorganisms.2020;8(11):1792.
15. Cholongitas E, Haidich AB, Apostolidou-Kiouti F, et al. Hepatitis b virus reactivation in HBsAg negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol.2018; 31: 480–490
16. Reddy KR, Beavers KL, Hammond SP, et al.American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148:215.
17. Loomba R and Liang TJ. Hepatitis B Reactivation Associated with Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology.2017;152(6):1297-1309
18. Faisal, H. T. ., Abid, M. K. ., & Abed, A. . (2022). Study Of Some Biochemical Parameters in Dose During Pregnancy in Goats. Journal Of Advanced Zoology, 43(1), 01–06. https://doi.org/10.17762/jaz.v43i1.109
19. Gulati, H. ., & Rana, S. . (2022). Habitat Preference and Current Threats to The Sarus Cranes Grus Antigone (Aves: Gruiformes:
Gruidae) In Important Bird Areas of Haryana, India: Implications for Determining Effective Conservation Actions. Journal Of Advanced
Zoology, 43(1), 07–16. Retrieved from http://jazindia.com/index.php/jaz/article/view/110
20. Mokhtar, A. R. R. A. S. . (2022). Development Of Saponin Based Wettable Powder Formulation from Phaleria macrocarpa To Control Pomacea maculate. Journal Of Advanced Zoology, 43(1), 17–31. Retrieved from http://jazindia.com/index.php/jaz/article/view/111
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.